Model of the Human Endometrium

NU 2020-166

INVENTORS

  • John Kessler*
  • Virginia Cheung
  • Chian-Yu Peng

SHORT DESCRIPTION

Methods and compositions to generate a multicellular model of the human endometrium by differentiating pluripotent stem cells into endometrial stromal fibroblasts and co-culturing with placenta-derived endometrial epithelial organoids, with applications in drug discovery and screening.

BACKGROUND

Current treatments for endometrial and reproductive diseases are limited by inadequate models for human implantation and placentation. Most existing non-human animal models do not share fundamental biological processes with the human endometrium, such as spontaneous decidualization, and no existing human cell cultures recapitulate the cyclic interactions between endometrial stromal and epithelial compartments necessary for decidualization and implantation. Thus, mechanistic studies of processes involved in reproductive diseases and the evaluation of pre-clinical drug action and safety have traditionally been a challenge.

ABSTRACT

The invention addresses the limitations in drug development for reproductive conditions by providing a robust protocol to differentiate induced pluripotent stem cells into endometrial stromal fibroblasts. These cells are then co-cultured with endometrial epithelial organoids derived from term placenta, creating a multicellular model that mimics the human endometrial environment. The model is capable of responding to hormonal treatments and withdrawals, allowing for the comprehensive study of biological processes and drug effects throughout the endometrial cycle. Additionally, it can facilitate the examination of drug interactions with trophoblasts, offering a valuable tool for evaluating drug impacts during human pregnancy.

APPLICATIONS

  • Drug screening for human endometrial effects
    • Enables testing of drugs specifically on the human endometrium.
  • Drug screening for implantation effects
    • Facilitates evaluation of drugs on endometrium/decidua implantation processes.
  • Testing for drug processing impacts
    • Assesses how drugs processed by the endometrium affect the placenta/fetus.
  • Cell replacement and gene therapy
    • Provides cells for therapeutic applications, including gene therapy.

ADVANTAGES

  • Human cell-based model
    • Utilizes human cells, eliminating the need for animal models.
  • Comprehensive cellular model
    • Incorporates both stromal and epithelial cell types of the human endometrium.
  • Cyclical hormone responsiveness
    • Allows study across the entire hormone cycle, providing dynamic insights.

PUBLICATIONS

IP STATUS

US Patent Pending

Stem Cell-Derived Endometrial Model for Drug Screening and Therapeutics

Patent Information: